30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

Anika's CINGAL Premarket Review to Proceed through FDA Center for Drug Evaluation and Research -

FDA has assigned Anika Therapeutics' CINGAL® to the Center for Drug Evaluation and Research for its premarket review.

CINGAL is the first combination viscosupplement formulated with Anika’s cross-linked sodium hyaluronate (currently marketed as single-injection MONOVISC®) and an FDA-approved steroid to treat inflammation.
Earlier this year, Anika announced positive results from its CINGAL 13-01 and 13-02 studies, demonstrating the efficacy and safety of a single injection of CINGAL for treatment of pain caused by knee osteoarthritis (OA), as well as the safety of a repeat injection.

CINGAL was approved in Canada as a medical device to treat pain associated with knee OA, and is under review in the EU.

Source: Anika Therapeutics, Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.